Recombinant Bovine IGF-like family receptor 1 (IGFLR1)

What is the IGF-1 receptor and what is its biological significance in bovine systems?

The IGF-1 receptor (IGF-1R) is a transmembrane receptor that belongs to the insulin receptor family. In bovine systems, as in other mammals, IGF-1R plays a crucial role in mediating the effects of insulin-like growth factors (IGFs), particularly IGF-1. This receptor is integral to numerous physiological processes including cell proliferation, growth, inhibition of apoptosis, and is linked with tissue development and tumor cell growth. IGF-1R signaling involves binding to both IGF-1 and IGF-2, resulting in the activation of downstream pathways, most notably the AKT signaling pathway. The receptor's activation is primarily modulated by growth hormone (GH), which stimulates IGF-1 production, predominantly in the liver . Understanding bovine IGF-1R is particularly important for agricultural research and comparative studies with human systems.

How does the structure of bovine IGF-1R compare to its human counterpart?

Bovine IGF-1R shares significant structural homology with human IGF-1R, making it a valuable model for comparative studies. Like its human counterpart, bovine IGF-1R is a tyrosine kinase receptor composed of two α and two β subunits, forming a heterotetramer. The receptor contains extracellular domains responsible for ligand binding (primarily in the α subunits) and intracellular domains with tyrosine kinase activity (in the β subunits). While the core functional domains are conserved between species, subtle differences in amino acid sequences can affect ligand binding affinities and downstream signaling dynamics. Cryo-electron microscopy studies of IGF-1R have revealed that ligand binding induces conformational changes that can either activate or inactivate the receptor, depending on the specific ligand and binding mode . These structural insights are essential for understanding species-specific responses to different IGF-1R-targeting compounds.

What are the main ligands for bovine IGF-1R and their relative binding affinities?

The primary ligands for bovine IGF-1R include:

• IGF-1 (insulin-like growth factor-1): The principal ligand with highest affinity

• IGF-2 (insulin-like growth factor-2): Binds with slightly lower affinity than IGF-1

• Insulin: Binds with significantly lower affinity compared to IGF-1 and IGF-2

Studies comparing recombinant, chemically-synthesized, and naturally purified bovine IGF-1 have shown that these different forms are equipotent in radioreceptor assays with IGF-1 or IGF-2 as radioligands . Interestingly, the N-terminal truncated, destripeptide derivative of IGF-1 shows approximately 7 times higher potency than standard IGF-1 in protein synthesis bioassays, although this increased activity is not associated with enhanced binding affinity to IGF-1R on target cells . Additionally, certain viral insulin-like peptides (VILPs) like those from Lymphocystis disease virus-1 (LCDV-1) can interact with IGF-1R with varying affinities, potentially antagonizing IGF-1 signaling without affecting insulin signaling .

What are the established methods for cloning and expressing recombinant bovine IGF-1R?

The expression of recombinant bovine IGF-1R typically begins with isolating and cloning the full-length cDNA. Based on established protocols for IGF-1 (which can be adapted for IGF-1R), the process involves:

• RNA extraction from bovine liver tissue, which is a primary site of IGF-1/IGF-1R expression

• Synthesis of single-strand cDNA through specific reverse transcription (RT) of target mRNA

• PCR amplification of the full-length receptor sequence

• Cloning into an appropriate expression vector (e.g., pTARGETTM vector has been successfully used for IGF-1)

• Transformation into competent cells (e.g., E. coli JM109) for initial propagation

• Subcloning into mammalian expression vectors for functional receptor expression

The complete protocol needs to be optimized for the larger and more complex IGF-1R sequence compared to IGF-1 itself. For mammalian expression systems, cell lines such as CHO, HEK293, or NIH-3T3 are commonly used to ensure proper folding and post-translational modifications of the receptor .

What are the optimal conditions for purifying functional recombinant bovine IGF-1R?

Purification of functional recombinant bovine IGF-1R requires careful consideration of multiple factors:

For functional studies, it's often preferable to purify the receptor in membrane fractions or reconstitute it into lipid nanodiscs to maintain the native conformation of the transmembrane and intracellular domains. Quality control typically involves verification of ligand binding capacity using radioreceptor assays or surface plasmon resonance (Biacore) with IGF-1 and IGF-2 as test ligands .

How can researchers evaluate the binding kinetics between bovine IGF-1R and its ligands?

Several complementary approaches can be used to characterize the binding interactions between bovine IGF-1R and its ligands:

• Radioreceptor assays: Using radiolabeled IGF-1 or IGF-2 as tracers to measure displacement by unlabeled ligands. This approach has been successfully used to compare different forms of IGF-1 and their binding to receptors .

• Surface plasmon resonance (Biacore): Provides real-time binding kinetics and allows determination of association (kon) and dissociation (koff) rate constants as well as equilibrium dissociation constants (Kd). This technique has been used to show that L2-Cmu (a murinized antibody) binds to and inhibits IGF-1R activation by both IGF-1 and IGF-2 with Ki values of approximately 3.3 nM .

• IGEN format assays: These electrochemiluminescence-based binding assays provide another platform to verify receptor-ligand interactions .

• Cellular binding assays: Using cells expressing bovine IGF-1R to assess binding of fluorescently labeled ligands via flow cytometry or microscopy.

For comprehensive characterization, researchers should employ multiple methods, as each provides different insights into the binding mechanism and may have different sensitivities to particular aspects of the interaction.

What methods are most effective for studying bovine IGF-1R signaling pathways?

To effectively study bovine IGF-1R signaling pathways, researchers can employ several complementary approaches:

• Western blotting: Essential for detecting receptor phosphorylation and activation of downstream signaling molecules such as AKT. This method has been used to demonstrate that pre-treatment with certain antibodies (e.g., L2-Cmu) can inhibit IGF-1-mediated activation of IGF-1Rs and insulin receptor/IGF-1R hybrid receptors by approximately 65% .

• Functional bioassays: For example, protein synthesis assays in myoblast cell lines (such as L6) can assess the functional consequences of receptor activation. Different forms of IGF-1 have been shown to stimulate protein synthesis with varying potencies .

• Phosphoproteomics: Mass spectrometry-based approaches to identify and quantify phosphorylation events throughout the signaling cascade.

• Reporter gene assays: Using constructs with response elements for downstream transcription factors to monitor pathway activation.

• Cell proliferation assays: To assess the mitogenic effects of IGF-1R activation, as IGF-1 is known to promote cell proliferation through its receptor .

• Selective pathway inhibitors: Using specific inhibitors of different branches of the signaling pathway to dissect the relative contributions of each to observed biological effects.

When designing these experiments, it's important to include appropriate controls, such as unstimulated cells, cells treated with IGF-1 alone, and cells treated with known inhibitors of the pathway.

How can bovine IGF-1R be used in studies of receptor antagonism and therapeutic development?

Bovine IGF-1R serves as a valuable model for studying receptor antagonism and developing therapeutics targeting the IGF system. Several approaches have proven effective:

• Monoclonal antibody development: The development of specific antibodies against IGF-1R, such as L2-Cmu (a murinized version of the anti-IGF-1R mAb), has demonstrated the ability to selectively inhibit IGF-1R signaling. These antibodies can bind to and inhibit IGF-1R activation by both IGF-1 and IGF-2 with high specificity (Ki = 3.3 nM) .

• Natural antagonist discovery: Studies of viral insulin-like peptides (VILPs) have revealed that molecules like scLCDV1-VILP can act as specific antagonists of IGF-1R signaling without affecting insulin signaling. These peptides engage IGF-1R in a unique manner, inducing conformational changes that lead to separation of transmembrane segments and receptor inactivation .

• Structure-based drug design: Understanding the detailed structural interactions between bovine IGF-1R and its ligands can inform the development of small molecule antagonists. Cryo-electron microscopy has revealed the specific conformational changes induced by different ligands, providing templates for drug design .

• Truncated IGF variants: N-terminal truncated derivatives of IGF-1 have shown increased potency in biological assays, suggesting that engineered variants of IGF-1 could serve as more potent agonists or antagonists .

These approaches contribute to the development of therapeutics targeting IGF-1R for various conditions including cancers and metabolic disorders, with the advantage that selective IGF-1R antagonists may not affect glucose metabolism .

What are the key considerations when designing experiments to study hybrid receptors containing bovine IGF-1R?

When studying hybrid receptors formed between bovine IGF-1R and insulin receptors (InsR/IGF-1R hybrid receptors), researchers should consider several critical factors:

• Expression system selection: Choose cell lines with minimal endogenous expression of either receptor to avoid interference from native receptors. NIH-3T3 mouse fibroblasts have been successfully used for studying hybrid receptor inhibition .

• Receptor quantification: Develop methods to quantify the relative expression levels of each receptor type and the proportion forming hybrids, as this affects ligand response profiles.

• Selective activation protocols: Design experimental protocols that can distinguish activation of hybrid receptors from homomeric IGF-1R or insulin receptors. This may involve selective ligands or inhibitors.

• Signaling pathway analysis: Determine whether hybrid receptors activate distinct signaling pathways compared to homomeric receptors. Pre-treatment with specific antibodies like L2-Cmu has been shown to inhibit IGF-1-mediated activation of both IGF-1Rs and hybrid receptors by approximately 65% .

• Physiological relevance: Consider the tissue-specific expression patterns of hybrid receptors in bovine systems and design experiments to reflect these physiological contexts.

• Species differences: Be aware that the formation and function of hybrid receptors may differ between bovine and human systems, affecting the translational relevance of findings.

By addressing these considerations, researchers can generate more reliable and physiologically relevant data on the complex interactions between IGF-1R and insulin receptors in bovine systems.

What animal models are most appropriate for studying bovine IGF-1R function in developmental and metabolic contexts?

Several animal models can be employed to study bovine IGF-1R function, each with specific advantages for different research questions:

• Bovine-specific studies: Native cattle models provide the most relevant context but present challenges in terms of handling, cost, and experimental manipulation.

• Mouse models with bovine IGF-1R: Transgenic mice expressing bovine IGF-1R (either replacing or alongside the endogenous receptor) offer a compromise between physiological relevance and experimental tractability.

• Age-appropriate models: For developmental studies, models should be selected based on the specific developmental stage of interest. For metabolic studies in adults, models aged 18 months or older may be more appropriate, as demonstrated in studies of IGF-1R modulation in aging mice .

• Sex-specific considerations: Include both male and female animals in studies, as the effects of IGF-1R signaling modulation have shown significant sex differences. For example, L2-Cmu (an IGF-1R mAb) preferentially improves female healthspan and increases median lifespan by 9% .

• Specific pathway reporters: Consider using animals with reporter constructs for downstream signaling to facilitate in vivo monitoring of receptor activation.

When conducting in vivo studies, careful attention should be paid to dosing regimens, as demonstrated in studies with L2-Cmu where animals were pre-treated with 20 mg/kg by intraperitoneal injection .

How can researchers effectively assess the impact of IGF-1R signaling on bovine growth and metabolic parameters?

To effectively assess the impact of IGF-1R signaling on bovine growth and metabolism, researchers should implement a multi-faceted approach:

• Growth measurements:

  • Linear growth measurements (height, length)

  • Body weight progression

  • Tissue-specific growth parameters (muscle mass, bone density)

• Metabolic assessments:

  • Glucose tolerance tests

  • Insulin sensitivity assays

  • Energy expenditure measurements

  • Body composition analysis (fat vs. lean mass)

• Molecular biomarkers:

  • Circulating IGF-1 and IGFBP levels

  • Receptor phosphorylation status in target tissues

  • Downstream signaling molecules (AKT, mTOR pathway components)

  • Gene expression profiling of IGF-responsive genes

• Protein synthesis quantification:

  • In vivo protein synthesis rate measurements

  • Muscle protein synthesis in response to IGF-1 stimulation

  • Anabolic response to feeding

• Long-term physiological outcomes:

  • Lifespan and healthspan metrics

  • Age-related disease incidence

  • Functional assessments throughout lifespan

Studies have demonstrated that targeting IGF-1R signaling can have significant effects on healthspan and lifespan, particularly in females, even when treatment is initiated at advanced age (18 months in mice) . This suggests that growth and metabolic parameters should be assessed both acutely and chronically to fully understand the role of IGF-1R in bovine physiology.

How might viral insulin-like peptides (VILPs) inform our understanding of bovine IGF-1R function and regulation?

Viral insulin-like peptides (VILPs) offer unique insights into IGF-1R biology that can be applied to bovine systems:

• Receptor selectivity mechanisms: Studies of LCDV1-VILP have revealed that while these peptides have very low affinity for the insulin receptor, single-chain (sc) LCDV1-VILP shows high affinity for IGF-1R. This selective binding allows for antagonism of IGF-1 signaling without affecting insulin signaling, providing a model for developing selective IGF-1R modulators .

• Novel binding modes: Cryo-electron microscopy has revealed that scLCDV1-VILP engages IGF-1R in a unique manner, inducing conformational changes that lead to separation of transmembrane segments rather than juxtaposition, resulting in receptor inactivation. This contrasts with the typical activation mechanism and provides insights into alternative methods of receptor regulation .

• Evolutionary adaptation insights: The existence of VILPs with high homology to human insulin and IGFs suggests evolutionary pressures in host-pathogen interactions that may have shaped IGF system function across species, including bovine.

• Therapeutic template potential: The specific antagonist properties of scLCDV1-VILP on IGF-1R signaling provide a natural template for developing treatments for conditions sensitive to IGF-1 without affecting glucose metabolism .

These viral peptides can serve as valuable tools for dissecting the structural and functional characteristics of bovine IGF-1R, potentially revealing novel regulatory mechanisms and therapeutic approaches.

What are the current challenges and future directions in developing selective modulators of bovine IGF-1R?

The development of selective modulators for bovine IGF-1R faces several challenges while offering promising future directions:

• Current challenges:

  • Achieving selectivity between IGF-1R and insulin receptor due to structural similarities

  • Developing compounds that modulate specific downstream pathways selectively

  • Creating modulators that work across species for translational research

  • Understanding the different effects of IGF-1R modulation in males versus females, as observed in mouse models

  • Optimizing dosing regimens for chronic administration

• Future directions:

  • Structure-guided design based on viral insulin-like peptides that show natural selectivity for IGF-1R over insulin receptor

  • Development of bispecific antibodies targeting unique epitopes on bovine IGF-1R

  • Exploitation of species-specific differences in IGF-1R structure for selective targeting

  • Investigation of allosteric modulators that fine-tune rather than completely activate or inhibit receptor function

  • Exploration of tissue-specific delivery systems to target IGF-1R modulation to relevant tissues

• Translational potential:

  • IGF-1R monoclonal antibodies have already been developed for clinical use in treating advanced stage cancers, suggesting a path forward for bovine applications

  • Late-life targeting of IGF-1R has shown promise in improving healthspan and lifespan in mice, suggesting potential applications in veterinary medicine

  • The ability to modulate IGF-1 signaling without affecting insulin/glucose homeostasis offers advantages for metabolic applications

Addressing these challenges will require interdisciplinary approaches combining structural biology, medicinal chemistry, and physiological studies in appropriate model systems.